Veterinary Medicine

Abigail Meadows brings a wealth of experience to Atlanta Institute of Aesthetics' esthetician school.

Atlanta (PRWEB) August 12, 2007 -- Atlanta Institute of Aesthetics (atlantainstituteofaesthetics.com), a division of Atlanta School of Massage, welcomes Abigail Meadows to the esthetician school as the new program director. Abigail will join the existing team, adding even further depth to this exemplary group of elite skincare experts.

Ms. Meadows received a Master's degree from Long Island University-Brooklyn and Arnold Marie Schwartz School of Pharmacy with a concentration in cosmetic chemistry. Further studies include cancer cell research at Harvard University. Abigail's advanced training in the cosmetic and health care industries led her to the field of aesthetics.

Abigail began her career as a makeup artist in 1991 and has worked with pageants and theatrical performances all over the world, including Broadway, off-Broadway, and movie productions. She had a strong desire to further her training and became qualified as a licensed esthetician and later as a licensed esthetics instructor. She continued her training at Atlanta School of Massage, where she graduated from the massage therapy program.

Abigail brings a distinctive blend of clinical and artistic training to Atlanta Institute of Aesthetics. She owned a day spa and wellness center, so also brings a wealth of real business experience. Atlanta Institute of Aesthetics welcomes Abigail and the unique combination of educational and business experience she brings to the school.

About the leading esthetician school: Atlanta Institute of Aesthetics

Atlanta Institute of Aesthetics was formed in 2002 as a division of Atlanta School of Massage. Named a 2004 School of Distinction by the Accrediting Commission of Career Schools and Colleges of Technology (ACCSCT) national accrediting agency, Atlanta School of Massage has been an international leader in massage therapy education for 25 years. Formed by the same management team, with the same high standards in mind, Atlanta Institute of Aesthetics is following the same path of excellence set by its parent company. Atlanta Institute of Aesthetics stands out amongst the multitude of esthetics schools operating across the country because:

• Our program is accredited by the ACCSCT.
• We are authorized by the US Department of Education to offer Title IV funding.
• We have 25 years of experience running a successful Massage Therapy school.
• We have recruited quality teachers from throughout the US and from Europe where the standards of skincare education are much more rigorous than those currently required in the United States.

Atlanta Institute of Aesthetics, a division of Atlanta School of Massage, is located at 2 Dunwoody Park, Atlanta Georgia 30338. For more information, call 1-888-276-6277 or visit atlantainstituteofaesthetics.com. For more information about the massage school, visit atlantaschoolofmassage.com.

##

Patents expiring will propel growth of generics in neurodegenerative drugs market.

(PRWEB) August 12, 2007 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest developments in the neurodegenerative disease and drug market.

"Neurodegenerative Disease Drug Market Analysis and Forecasts 2007" finds that drug trials in the neurodegenerative sector have yielded hopeful results, suggesting that the market is set for expansion. The report reveals that the Neurodegenerative market was worth over $16 billion in 2006, with growth anticipated to exceed $18 billion in 2007.

The report is a comprehensive study on the major neurodegenerative
diseases- Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Neuropathic pain. It also looks at rarer genetic disorders like Huntington Disease as well the progressive neurodegenerative disease Amyotrophic Lateral Sclerosis. It records how these diseases place financial pressures on national healthcare services.

Authors of the report explain that there is a worldwide ageing of the Baby Boom generation, coupled with a rise in longevity. These factors are major catalysts in the long-term revenue growth in the pharmaceutical/health care sector, they claim.

The study analyses periods of sustained revenue growth in the 2007-2012 timeframe, and turns the spotlight on how patents expiring on major blockbuster drugs in the neurodegenerative segment in 2012, will boost the revenues in the generics market.

Market leaders like Biogen Idec, Elan, Eli Lilly, Novartis and Pfizer are expected to see major leaps in global annual earnings following advancements in the pharmaceutical and healthcare sector, say the authors.

Analysts have addressed key issues affecting the neurodegenerative market such as exploring whether stem cell research is the answer to these diseases. They have also predicted the most successful drugs in the next five years, and highlighted the current therapies that show the most revenue generating potential.

The report pinpoints the regions that show the highest prevalence of the diseases today and extrapolate available data to make predictions of disease incidence up to 2020. It also profiles the market leaders in neurodegenerative therapy, outlines current approved therapies and identifies the first line drugs coming off patent by 2012. The study values the market for 2007 and forecasts how much it will be worth in the next five years.

"Neurodegenerative Disease Drug Market Analysis and Forecasts 2007" is available in pdf format from Piribo. For more information, go to:
http://www.piribo.com/publications/generic_drugs/neurodegenerative_disease_drug_market_analysis_forecasts_2007.html

Piribo product ID: VIS055

About Piribo.
Piribo (http:www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

##

Parallel trade all set to get a grip on the U.S pharmaceutical market.

(PRWEB) August 12, 2007 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest developments in parallel trade in the United States, and how it affects the pharmaceutical industry.

"Parallel Trade - US Lawmakers allow imported prescriptions drugs" forecasts that parallel trade is on the verge of moving from the EU into other global markets. The EU has long supported the practice claiming it is an important driving force for market integration where there are important differences in price between member states.

Parallel trade is a controversial topic in the pharmaceutical industry today, and has been a subject of much debate since it has both supporters and detractors. But does parallel trade diminish the quality and safety of drugs?

The report highlights how it is impossible to ascertain the origin of an imported drug through this system. This uncertainty, says the report, could lead to scenarios where consumers believe that imported drugs enter the US from Canada, UK or European countries, when in reality the source country for the drug is elsewhere. It also looks at issues surrounding the repackaging of drugs.

The study surveys whether developing countries perceive parallel trade as a benefit for cheap drugs and predicts how long this is perception is likely to continue. It also assesses how much pharmaceutical companies stand to lose this year from the practice. Analysts take into account how parallel trade is going to shape up as the US is seen as a favourable market, and that the EU is soon going to comprise 27 countries.

Authors note that pharmaceutical companies have long pinned the blame for huge losses in revenue, which in turn affects innovation, on parallel trade. The practice is also seen as the gateway for counterfeit drugs entering the supply chain, they say.

The report cites the recent removal of three batches of counterfeit drugs by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These were copies of Eli Lilly's antipsychotic drug, Zyprexa and Sanofi-Aventis and Bristol Myers Squibb's Plavix.

"Parallel Trade - US Lawmakers allow imported prescriptions drugs" addresses key question such as why pharmaceutical companies are not being protected by regulatory bodies, and how far companies can legally protect themselves. It looks at how price linking can help stall parallel trade without significant revenue drops. Primarily, the study outlines how parallel trade or reimportation affects the US and Canada.

"Parallel Trade - US Lawmakers allow imported prescriptions drugs" is available in pdf format from Piribo. For more information, go to: http://www.piribo.com/publications/prescription_drugs/parallel_trade.html

Piribo product ID: VIS056

About Piribo.
Piribo (http:www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

##

NCH Swift Sound Software announce the release of their first port to the Linux platform, the transcription player, Express Scribe.

Canberra, Australia (PRWEB) August 11, 2007 -- NCH Swift Sound Software, specialists in audio, video and business applications, announce the release of Express Scribe for Linux.

"We are thrilled to offer one of the best free audio players for typists on the market for the Linux platform," said Stephanie Lee, marketing manager for the Australian company. "Although we have worked hard over the last few years to make our software compatible with Linux operating systems through the WINE emulator we recognised the need to start porting our applications for Linux users. One of our biggest challenges was to make the installation as generic as possible to suit all the main flavours of Linux."

Express Scribe is an audio player specifically designed for the playback of dictation or other audio recordings. It features variable speed playback, automatically checks and downloads files from FTP servers, email or a local area network and supports a large range of audio file formats including wav, mp3, wma, Olympus, Sony, Phillips and Sanyo digital formats as well and many more. Audio from video files can also be loaded for subtitle work.

"Of course the latest version of Express Scribe for Linux is free," said Stephanie. "It has all the features of the Windows version including the Scribe Mini which allows typists to reduce the size of the application to roughly an inch (2.5 cm) and it can be controlled by foot pedals and hot keys."

NCH Swift Sound is a leader in business audio technology. Since 1993 the software development team has released more than 40 Windows, Mac, Linux, Palm and Pocket PC applications which are now leaders in their classes and have been awarded for software excellence.

For more information see www.nch.com.au and www.nchsoftware.com.

##

Elad Levinson of Interaction Associates and award-winning author Christine Arena will present "The Business Case for Corporate Social Responsibility Effectiveness: Going Beyond Notions of 'Good-Bad' to Increase Shareholder Value" to the Northern California Chapter of the Association for Strategic Planning. The workshop will take place Thursday, September 20th, 2007, from 7:30 to 10:30 am at the City Club of San Francisco, 155 Sansome Street, 9th Floor, Bechtel Room, San Francisco, CA 94104.

San Francisco, CA (PRWEB) August 11, 2007 -- Interaction Associates announced that its Director of Corporate Social Responsibility Consulting and Services, Elad Levinson, will present with author Christine Arena on the topic of Corporate Social Responsibility Effectiveness in San Francisco.

"The Business Case for Corporate Social Responsibility Effectiveness: Going Beyond Notions of 'Good-Bad' to Increase Shareholder Value" will take place at the Northern California Chapter of the Association for Strategic Planning meeting, Thursday, September 20th, 2007, from 7:30 to 10:30 am at the City Club of San Francisco, 155 Sansome Street, 9th Floor, Bechtel Room, San Francisco, CA 94104.

The two experts will look at Corporate Social Responsibility as a branding advantage, a means of attracting conscious customers, and a way of complying with regulations . . . and demonstrate that none of these are particulary effective strategies.

They will examine CSR strategy as a matter of innovation, and show how it can be integrated into the regular process of Strategic Planning. And they will point to a key accelerator - collaboration -- that must be considered in designing or developing a strategic approach to CSR.

Attendees will:

• Learn the 10 effectiveness triggers that reflect and drive CSR performance.
• See how the vital link between collaboration, innovation, and success with corporate responsibility works at companies that profit from CSR strategy.
• Discover a tool that can be used to measure collaborative capacity and capability when developing strategy for your clients.
• Understand the benefits to your clients of demonstrating responsiveness so that your clients can enjoy the benefits of CSR strategy as a competitive advantage.

For more information or to attend, please email Stacy McCarthy smccarthy(at)sapiencegroup.net by September 18, 2007.

About the Presenters
Christine Arena is the host of Focus Earth TV, and the award-winning author of two books, Cause for Success: 10 Companies that Put Profits Second and Came in First (New World Library, November 2004), and The High-Purpose Company: The Truly Responsible (and Highly Profitable) Firms that are Changing Business Now (Collins, January 2007). Christine serves as a strategic partner to Interaction Associates, and sits on the advisory boards of green business ventures IdealBite.com and Re:Vision.

Elad Levinson, LCSW, is Director, Corporate Social Responsibility Consulting and Services for Interaction Associates. He has more than 35 years' experience in the fields of organizational development, learning and development, and human resources. Elad is a pioneer in the application of Hans Selye's Stress Theory to organizational behavior. Elad is the author of Managing Stress to Increase Productivity.

About Interaction Associates
Interaction Associates, Inc. is a leading global innovator in learning, leadership development, collaboration and performance improvement solutions for Fortune 1000 companies. The firm has offices in Cambridge, MA and San Francisco. For nearly 40 years, IA has helped clients focus on the people side of their business through leadership development, coaching, and performance improvement solutions.

This press release was distributed through eMediawire by Human Resources Marketer (HR Marketer: www.HRmarketer.com) on behalf of the company listed above.

##